Israel biotech seeks investment
This article was originally published in Clinica
If $3-4 billion of public and private funds were invested in the Israeli biotechnology sector, sales would be boosted to somewhere in the region of $4 billion within 5-7 years. This is the view put forward by Professor Haim Aviv at a meeting of the board of governors of the Israel-US Binationational and Industrial Research Foundation (BIRD). He said that currently Israel's 160 biotech companies make aggregate sales in the region of $800 million, but that the sector had enjoyed phenomenal growth over the past decade. Further growth was, however, being hampered by lack of financial resources and managerial skill, Professor Aviv said.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.